Generic Name and Formulations:
Ciclopirox 8%; topical soln (nail lacquer).
Valeant Pharmaceuticals, Inc
Indications for PENLAC:
Mild to moderate onychomycosis of the fingernails and toenails (without lunula involvement) due to Trichophyton rubrum in immunocompetent patients, as part of a comprehensive management program (including professional removal of unattached, infected nails).
Apply thin layer evenly once daily over previous coat(s) to entire nail and surrounding 5mm of skin (preferably at bedtime or 8 hours before washing). If possible, apply to nail bed, hyponychium, and under surface of nail plate when it is free of the nail bed. Remove with alcohol once per week (file and trim nails while nail is free from drug). Repeat this regimen for up to 48 weeks. Improvement may take up to 6 months. Healthcare professional: Remove unattached infected nail as frequently as monthly, trim onycholytic nail, and file excess horny material.
Discontinue if sensitivity or chemical irritation occurs. Immunosuppressed or immunocompromised. HIV positive. Organ transplant recipients. Seizures. Severe plantar (moccasin) tinea pedis. Diabetes, diabetic neuropathy: consider risk of nail care before prescribing. Avoid eyes, mucous membranes. Product is flammable. Pregnancy (Cat.B). Nursing mothers.
Concomitant systemic antifungals for onychomycosis: not recommended. Do not use nail polish or other nail cosmetics on treated nails.
Rash, nail disorders (e.g., shape change, irritation, ingrown toenail, discoloration), local reactions (e.g., burning sensation, erythema).
Nail lacquer—6.6mL (w. applicator)
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally